BBT 401

Drug Profile

BBT 401

Alternative Names: BBT-401-1S

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Korea Research Institute of Chemical Technology; Sungkyunkwan University
  • Developer Bridge Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Neuroprotectants; Peptides
  • Mechanism of Action Interleukin-1 receptor-antagonist protein inhibitors; Myeloid differentiation factor 88 inhibitors; Ubiquitin protein ligase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis
  • Preclinical Age-related macular degeneration; Multiple sclerosis

Most Recent Events

  • 05 Apr 2018 Bridge Biotherapetuics plans to file an IND application with the the US FDA for Age-related macular degeneration in second quarter of 2018
  • 05 Apr 2018 Bridge Biotherapeutics plans a phase I/II trial for Multiple scleroris in 2018
  • 05 Apr 2018 Bridge Biotherapeutics plans a phase I/II trial in Multiple sclerosis in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top